Lexeo Therapeutics, Inc.
A clinical-stage company developing AAV gene therapies for genetic diseases.
LXEO | US
Overview
Corporate Details
- ISIN(s):
- US52886X1072
- LEI:
- Country:
- United States of America
- Address:
- 345 PARK AVENUE SOUTH, 10010 NEW YORK
- Website:
- https://www.lexeotx.com/
- Sector:
- Manufacturing
Description
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to developing gene therapies for genetically defined diseases. The company is advancing a diverse pipeline of investigational adeno-associated virus (AAV)-based gene therapy candidates. Its primary areas of focus are rare cardiovascular diseases and APOE4-associated Alzheimer's disease. Lexeo's strategy centers on addressing conditions with high unmet medical needs by leveraging pioneering science, including research originating from institutions such as Weill Cornell Medicine, to develop treatments with curative potential.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Lexeo Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Lexeo Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Lexeo Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
